Junya Kawai

Dr. Junya Kawai

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2013 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
YMYutaka Matsuo
Yutaka Matsuo
JKJunya Kawai
Junya Kawai
HIHiroshi Inada
Hiroshi Inada
TNTakafumi Nakagawa
Takafumi Nakagawa
HOHitoshi Ota
Hitoshi Ota
ENEiichi Nakamura
Eiichi Nakamura

15 February 2016 in International Journal of Oncology
Verified
Journal Article
Closed access
TSTakamitsu Shimizu
Takamitsu Shimizu
JKJunya Kawai
Junya Kawai
KOKenji Ouchi
Kenji Ouchi
HKHaruhisa Kikuchi
Haruhisa Kikuchi
YOYoshiteru Osima
Yoshiteru Osima
RHRikiishi Hidemi
Rikiishi Hidemi
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

14 September 2016 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
HKHaruhisa Kikuchi
Haruhisa Kikuchi
TNTakehiro Nishimura
Takehiro Nishimura
EKEunsang Kwon
Eunsang Kwon
JKJunya Kawai
Junya Kawai
YOYoshiteru Oshima
Yoshiteru Oshima

29 October 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HTHiroyuki Tada
Hiroyuki Tada
KKKazuyoshi Kawahara
Kazuyoshi Kawahara
HOHiraku Osawa
Hiraku Osawa
LSLi-Ting Song
Li-Ting Song
KNKento Numazaki
Kento Numazaki
SSShunji Sugawara
Shunji Sugawara

9 January 2023 in Frontiers in Nutrition
Verified
Journal Article
Open access
YNYuichiro Nishimoto
Yuichiro Nishimoto
JKJunya Kawai
Junya Kawai
KMKoichiro Mori
Koichiro Mori
THTenagy Hartanto
Tenagy Hartanto
KKKaori Komatsu
Kaori Komatsu
SFShinji Fukuda
Shinji Fukuda
Background: Mushrooms are rich in dietary fiber, and fiber intake has been reported to increase the levels of short-chain fatty acids (SCFAs). It has also been reported that SCFAs promote immunoglobulin A (IgA) production, indicating involvement in systemic immunity.Objectives: The objective of this study was to evaluate the effects of mushroom consumption on the amount of intestinal IgA. We also aimed to comprehensively evaluate the gut microbiota and intestinal metabolome and to conduct an exploratory analysis of their relationship with IgA.Methods: Healthy adults (n = 80) were enrolled in a parallel group trial. Participants consumed a diet with mushrooms or a placebo diet once daily for 4 weeks. Gut microbiota profiles were assessed by sequencing the bacterial 16S ribosomal RNA-encoding gene. Intestinal metabolome profiles were analyzed using capillary electrophoresis-time of flight mass spectrometry (CE-TOFMS).Results: Mushroom consumption tended to increase IgA levels at 4 weeks of consumption compared to those in the control group (p = 0.0807; Hedges’ g = 0.480). The mushroom group had significantly higher levels of intestinal SCFAs, such as butyrate and propionate, than the control group (p = 0.001 and 0.020; Hedges’ g = 0.824 and 0.474, respectively). Correlation analysis between the changes in the amount of intestinal IgA and the baseline features of the intestinal environment showed that the increasing amount of intestinal IgA was positively correlated with the baseline levels of SCFAs (Spearman’s R = 0.559 and 0.419 for butyrate and propionate, respectively).Conclusion: Consumption of mushrooms significantly increased the intestinal SCFAs and IgA in some subjects. The increase in intestinal IgA levels was more prominent in subjects with higher SCFA levels at baseline. This finding provides evidence that mushroom alters the intestinal environment, but the intensity of the effect still depends on the baseline intestinal environment. This trial was registered at www.umin.ac.jp as UMIN000043979.

3 October 2018 in Bioscience, Biotechnology, and Biochemistry
Verified
Journal Article
Open access
PDF file
JKJunya Kawai
Junya Kawai
YHYuka Higuchi
Yuka Higuchi
MHMitsuru Hirota
Mitsuru Hirota
NHNoriyasu Hirasawa
Noriyasu Hirasawa
KMKoichiro Mori
Koichiro Mori
Grifola frondosa is an edible mushroom consumed as a health food and/or traditional medicine in Asia. However, the anti-allergic effects of G. frondosa are not yet understood. In this study, we demonstrated the effects of G. frondosa extract (GFE) on IgE-mediated allergic responses, using antigen-stimulated RBL-2H3 cells. Three active compounds: ergosterol, 6β-methoxyergosta-7,22-dien-3β,5α-diol (MEDD), and 6-oxoergosta-7,22-dien-3β-ol (6-OXO) were isolated from GFE and shown to inhibit the antigen-induced release of β-hexosaminidase and histamine. Among the three active components, we focused on ergosterol because of its high content in GFE. Ergosterol inhibited the aggregation of high-affinity IgE receptor (FcεRI), which is the first step in the activation of mast cells and antigen-induced tyrosine phosphorylation. Furthermore, ergosterol suppressed antigen-increased IL-4 and TNF-α mRNA. Taken together, our findings suggest that G. frondosa, including ergosterol and its derivatives as active components, has the potential to be a novel functional food that prevents type I allergies.